Hundreds of novel medicines are expected to gain approval between 2016 and 2020 but will the NHS make the most of the best new drugs, or limit access and uptake as in previous years?
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
